Evidence mapPaperPMID 39789717Full record

ArticleNephrology (Carlton, Vic.)2025

Mind the gap in kidney care: Translating what we know into what we do.

Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud and 9 more

Abstract readEditorial
In one paragraph

Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Valerie A LuyckxDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Katherine R TuttleProvidence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.
Dina AbdellatifDepartment of Nephrology, Cairo University Hospital, Cairo, Egypt.
Ricardo Correa-RotterDepartment of Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.
Winston W S FungDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0000-0001-7676-7628
Agnès HarisNephrology Department, Péterfy Hospital, Budapest, Hungary.
Li-Li HsiaoRenal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Makram KhalifeISN Patient Liaison Advisory Group, Brussels, Belgium.
Latha A KumaraswamiTamilnad Kidney Research (TANKER) Foundation, Chennai, India.
Fiona LoudISN Patient Liaison Advisory Group, Brussels, Belgium.
Vasundhara RaghavanISN Patient Liaison Advisory Group, Brussels, Belgium.
Stefanos Roumeliotis2nd Department of Nephrology, AHEPA University Hospital Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID https://orcid.org/0000-0002-9423-649X
Marianella SierraISN Patient Liaison Advisory Group, Brussels, Belgium.
Ifeoma UlasiDepartment of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria.
Bill WangISN Patient Liaison Advisory Group, Brussels, Belgium.
Siu-Fai LuiDivision of Health System, Policy and Management, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
Vassilios Liakopoulos2nd Department of Nephrology, AHEPA University Hospital Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Alessandro BalducciItalian Kidney Foundation, Rome, Italy.
World Kidney Day Joint Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

Indexed as

Kidney DiseasesNephrologyProfessional Practice GapsDisease ProgressionHumansRisk Factorschronic kidney diseaseequitykidney carepublic healthworld kidney day

Identifiers

PMID39789717
PMCPMC11718150

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.